Inclusion Criteria:

- Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III
according to the International Staging System ISS (see appendix A), i.e. at least one
of the CRAB criteria should be present;

- Measurable disease as defined by the presence of M-protein in serum or urine (serum
M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain
ratio;

- Age 18-65 years inclusive;

- WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by
comorbid conditions);

- Negative pregnancy test at inclusion if applicable;

- Written informed consent.

Inclusion for randomisation 1:

- WHO performance 0-2;

- Bilirubin and transaminases < 2.5 times the upper limit of normal values;

- A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according
to national guidelines).

Inclusion for randomisation 2:

- Bilirubin and transaminases < 2.5 times the upper limit of normal values;

- ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;

- Patient is able to adhere to the requirements of the Lenalidomide Pregnancy
Prevention Risk Management Plan.

Exclusion Criteria:

- Known intolerance of Boron;

- Systemic AL amyloidosis;

- Primary Plasmacell Leukemia;

- Non-secretory MM;

- Previous chemotherapy or radiotherapy except local radiotherapy in case of local
myeloma progression or corticosteroids maximum 5 days for symptom control;

- Severe cardiac dysfunction (NYHA classification II-IV);

- Significant hepatic dysfunction, unless related to myeloma;

- Patients with GFR <15 ml/min,

- Patients known to be HIV-positive;

- Patients with active, uncontrolled infections;

- Patients with neuropathy, CTC grade 2 or higher;

- Patients with a history of active malignancy during the past 5 years with the
exception of basal carcinoma of the skin or stage 0 cervical carcinoma;

- Patients who are not willing or capable to use adequate contraception during the
therapy (all men, all pre-menopausal women);

- Lactating women.

Exclusion for randomisation 1:

- Severe pulmonary, neurologic, or psychiatric disease;

- CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;

- Allogeneic Stem Cell Transplantation (Allo SCT) planned;

- Progressive disease.'

Exclusion for randomisation 2:

- Progressive disease;

- Neuropathy, except CTCAE grade 1;

- CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.